Internal Reference Number: FOI_6409
Date Request Received: 21/12/2021 00:00:00
Date Request Replied To: 22/12/2021 00:00:00
This response was sent via: By Email
Request Summary: Analysing the incidence and treatment of Haemophilia A
Request Category: Companies
| Question Number 1: How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. | |
| Answer To Question 1: Section 38 refusal notice applied | |
| Question Number 2: In the last three months, how many patients have been treated by your haemophilia centre with the following products? • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra • NovoEight • NovoSeven RT • Obizur • Refacto AF | |
| Answer To Question 2: Section 38 refusal notice applied | |
| To return to the list of all the FOI requests please click here |
Our staff at ÃÛÌÒÓ°Ïñ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ÃÛÌÒÓ°Ïñ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
